by: Laird Harrison
VIENNA — For patients with bilateral late-stage age-related macular degeneration (AMD), an implantable miniature telescope is effective in patients younger than 75 years, according to results of a 5-year study.
“Younger patients probably have a greater ability to adapt,” David Boyer, MD, from the University of Southern California in Los Angeles, told Medscape Medical News.
The miniature telescope, developed by VisionCare Ophthalmic Technologies, was approved by the US Food and Drug Administration (FDA) in 2010 for use in patients aged 75 years and older with moderate to severe central visual impairment from end-stage macular degeneration. Earlier results from this study supported the approval.
At the request of the FDA, Dr Boyer and colleagues extended the study to look at long-term results. They also conducted a subgroup analysis for patients according to age.
On the basis of their findings, the indication for the telescope was expanded by the FDA to include patients aged 65 to 75 years in October 2014.
The data were published online June 17 in the Journal of Clinical Ophthalmology and presented here at the American Society of Retina Specialists (ASRS) 2015 Annual Meeting.
The miniature telescope can help patients whose AMD makes the typical lens replacement for cataract treatment less effective. In such patients, “if you put a regular lens in, it focuses the light to the area of the retina that is damaged,” Dr Boyer explained.
Instead, the miniature telescope focuses on an undamaged part of the retina. “It allows them to see their grandchildren,” he said.
After removing the eye’s lens, surgeons place the implant in the capsular bag. It uses natural eye movements to provide 2.7 times magnification.
The researchers followed 217 patients who underwent implantation in one eye; the fellow eye served as the control group.
The mean age of the patients was 76 years. All had AMD and moderate to profound bilateral central visual acuity loss (20/80 to 20/800) from untreatable geographic atrophy, disciform scars, or both.
For the analysis, the patients were stratified by age at study enrollment: 75 years and older, 65 to 75 years, and younger than 65 years………
Read more: http://www.medscape.com/viewarticle/847852
Image: Image was provided by CentraSight and we were given permission to use it.
by: Laird Harrison